PET MRI in Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
This study will assess the use of position emission tomography/magnetic resonance imaging (PET/MRI) using ultra-small-superparamagnetic particles of iron oxide (USPIO) as a contrast agent in patients with coronary artery disease.

Detailed Description
-----------------
Positron emission tomography/magnetic resonance imaging (PET/MRI) has the potential to provide detailed information on coronary artery anatomy, the presence of coronary artery stenosis, the composition of atherosclerotic plaque using MRI tissue characterisation and information about the underlying biological processes using targeted PET tracers. Ultra-small-superparamagnetic particles of iron oxide (USPIO) have a long blood pool half-life so are an ideal contrast agent for PET/MRI imaging. This study will assess the use of PET/MRI with USPIO in patients with stable coronary artery disease and recent acute myocardial infarction.

Official Title
-----------------
Combined Magnetic Resonance Coronary Angiography and Positron Emission Tomography in Patients With Coronary Artery Disease

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Diagnostic Test: PET/MRI
* Diagnostic Test: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteers to undergo MRI imaging will be over the age of 18 years and able to provide informed consent. Patients with coronary artery disease to undergo PET/MRI will have multi-vessel disease (≥2 vessel coronary artery disease with ≥ 50% cross-sectional luminal stenosis). able to provide informed consent over the age of 40 years Exclusion Criteria: inability or unwillingness to undergo magnetic resonance imaging or positron emission tomography renal failure (Serum creatinine >200 umol/L or estimated glomerular filtration rate <30 mL/min hepatic failure pregnancy inability to provide informed consent contraindications to undergoing MRI scanning contraindications to contrast agents not included above including evidence of iron overload, known allergy to constituents of the contrast agents, and anaemia not caused by iron deficiency

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy volunteers<br>Healthy volunteers to undergo MRI using USPIO contrast | Diagnostic Test: MRI<br>* MRI with USPIO contrast<br>|
| Stable coronary artery disease<br>Patients with coronary artery disease without recent (3 months) acute coronary syndrome or revascularisation | Diagnostic Test: PET/MRI<br>* PET/MRI with USPIO contrast<br>|
| Recent acute coronary syndrome<br>Patients with recent (3 months) type 1 myocardial infarction | Diagnostic Test: PET/MRI<br>* PET/MRI with USPIO contrast<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PET/MRI findings | The primary endpoint will be the difference in MRI and PET characteristics of atherosclerotic plaques in patients with and without recent acute coronary syndromes. | Immediately after PET/MRI scan | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PET/MRI, ultra-small-superparamagnetic particles